Maternal death · women during pregnancy
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Maternal death · women during pregnancy
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
All‐cause mortality (outcome collected through first event: death, hospital discharge, hospital transfer, or 120 days after birth) · preterm infants with or at risk of respiratory distress syndrome
Inositol supplementation IV initially followed by enteral… showed no clear difference in all‐cause mortality (outcome collected through first event: death,… compared with placebo (moderate certainty).
1 finding from 1 review
Mortality In the early postoperative period (≤ 30 days) · adult participants undergoing cardiac and major abdominal surgery
It is very uncertain whether preoperative inspiratory muscle training changes all‐cause mortality within 30 days during postoperative period compared with usual care, non‐exercise intervention (very low certainty).
1 finding from 1 review
All‐cause mortality up to 30 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
It is very uncertain whether summary of findings table ‐ Methylprednisolone changes all‐cause mortality up to 30 days compared with dexamethasone (very low certainty).
1 finding from 1 review
All‐cause mortality up to 120 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Neonatal mortality · very preterm infants at risk of intraventricular hemorrhage
It is very uncertain whether antithrombin changes neonatal mortality (all‐cause, < 28 days of age) compared with placebo (very low certainty).
1 finding from 1 review
All‐cause mortality Up to 28 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
FIBRINOGEN: Therapeutic trials: intervention showed no clear difference in all‐cause mortality Up to 46 days post‐operatively compared with inactive Control (high certainty).
1 finding from 1 review
All‐cause mortality Up to 28 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
2 findings from 1 review
All‐cause mortality Up to 28 days following admission · the prevention and treatment of bleeding in patients without haemophilia
FIBRINOGEN: Therapeutic trials: intervention showed no clear difference in all‐cause mortality Up to 28 days following admission compared with inactive Control (moderate certainty).
1 finding from 1 review
All‐cause mortality Up to 7 days post‐operatively or hospital discharge · the prevention and treatment of bleeding in patients without haemophilia
1 finding from 1 review
All‐cause mortality In‐hospital mortality up to 30 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
FIBRINOGEN: Therapeutic trials: intervention showed no clear difference in all‐cause mortality In‐hospital mortality up to 30 days… compared with inactive Control (low certainty).
1 finding from 1 review
Mortality (all‐cause) (up to 30 days) · people undergoing initial treatment for KD
1 finding from 1 review
Intervention not reported
All‐cause mortality at day 28 · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease
The intervention may leads to lower all‐cause mortality at day 28 (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at day 28 · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities
It is very uncertain whether the intervention changes all‐cause mortality at day 28 (very low certainty).
1 finding from 1 review
All‐cause mortality by day 60 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Bamlanivimab showed no clear difference in all‐cause mortality by day 60 compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality by day 30 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Casirivimab/imdevimab showed no clear difference in all‐cause mortality by day 30 compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at day 28 · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…
It is very uncertain whether the intervention changes all‐cause mortality at day 28 (very low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at day 28 · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
The intervention showed no clear difference in all‐cause mortality at day 28 (moderate certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality up to 30 days · people with neutropenia or neutrophil dysfunction
It is very uncertain whether the intervention changes all‐cause mortality up to 30 days (very low certainty).
1 finding from 1 review